Por Stiven Cartagena
April 30, 2026
By 2025, a quarter of organizations in the life sciences sector had already integrated artificial intelligence at scale. However, despite continued investment, the expansion of this technology has largely stalled.
One of the reasons is the high level of regulation that characterizes the sector. For some, this is a concerning trend: if AI-generated content does not undergo rigorous controls, misinformation can increase.
In fields such as medicine and science, the impact of AI on communications raises particular concern. These are sectors that demand absolute precision, and addressing this challenge is key to connecting with the public and ensuring that new treatments truly reach patients.
To help life sciences companies and their agencies solve this dilemma—and accelerate the delivery of results—startup Prezent AI has launched a new solution designed to power the sector’s entire communication ecosystem: Prezent Vivo.
A year ago, the company announced the closing of a $30 million Series B funding round. This capital injection raised the company’s valuation to $400 million, bringing it close to becoming the sector’s first unicorn.
“The future of Life Sciences communication is AI and experts, fused into one,” said Rajat Mishra, CEO and Co-Founder of Prezent.
The Vivo platform delivers AI-powered communication at scale across the full spectrum of content deliverables. This includes the entire product lifecycle, ranging from congress posters, data visualization, scientific documents, brochures, narrative presentations for MSLs, advisory board materials, to national sales meetings and more.
For Francine Carrick, recently appointed President of Prezent Vivo, the rise of AI-generated content is not something to fear, but rather a new opportunity.
“we’re at this incredible inflection point where evolving regulations, increasingly complex data, and the rise of AI are fundamentally reshaping how we communicate science.”
Before joining BCB Group as Managing Director of Medical Communications in 2024, Carrick spent nearly seven years leading various aspects of business and client strategy at Envision Pharma Group.
Since then, she has worked as Chief Commercial Growth Officer for private equity-backed companies. This means Carrick has deep expertise in the field of medical communications and understands the barriers that have limited experts in this space.
“Imagine publications that adapt in real time to new evidence, or tools that help authors surface insights buried in mountains of clinical data. We’re just scratching the surface,” she explained.
Now, Carrick will apply this same innovative vision to position Prezent Vivo as a way to provide life sciences companies and communication agencies with reliable access to AI.
Without access to AI tools with scientific depth and rigorous accuracy, it has not been possible to scale these technologies. Outsourcing content creation to traditional agencies has always been an option, but the process is slow due to the specialized nature of the work.
Prezent Vivo brings AI-powered communication to the life sciences industry, combining for the first time a customized large language model (LLM)—designed to understand the context and nuances of the industry—with subject matter experts.
Prezent’s original communication platform will continue with its presentation tool for companies across various sectors. Vivo complements this core business model by offering a broader range of communication solutions, along with much deeper industry expertise to properly serve life sciences and biopharmaceutical companies.
While experts in the biological sciences sector need to communicate clearly and combat misinformation, concerns around regulatory compliance and accuracy have historically limited the use of AI to create communication materials. Prezent Vivo offers a vision of how this technology can be used to amplify the voice of scientific experts and improve patient engagement.
